Close Menu

NEW YORK (GenomeWeb) — CancerLinQ has entered into an agreement with Tempus and Precision HealthAI to accelerate development and delivery of high-quality, deidentified clinical databases, CancerLinQ said yesterday.

The databases are intended for use by CancerLinQ, a non-profit subsidiary of the American Society of Clinical Oncology, as well as its oncologist subscribers, partners, and the broader cancer community. They will be made available through the core CancerLinQ quality improvement platform and the organization's CancerLinQ Discovery service.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Jun
08
Sponsored by
Qiagen

Cancer is a complex and heterogeneous disease requiring patient-specific molecular analysis to support treatment decisions.

Jun
18
Sponsored by
Canexia Health

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019.